Patrick J. Balthrop is currently a Director at Oxford Immunotec Global, Personalis, Inc. and Concert Genetics. He is an advisor to Water Street Healthcare Partners and the Founding Principal of Apalachee Ventures, an investment and advisory firm. Patrick previously held positions of CEO, President and Director at Luminex, and President at Fisher Healthcare (then Fisher Scientific). He has also held a number of positions within Abbott Laboratories, including President of Abbott Vascular and Corporate VP, Worldwide Commercial Operations. Patrick has an MBA from the Kellogg School of Management, Northwestern University and a BS in Biology from Spring Hill College.
Supervisory Board Member, member of the Audit Committee, member of the Technical Committee and member of the Governance and Remuneration Committee
Christoph is an investment manager at Korys, focusing on the fund investments in the life science sector in both the private and public equity market. In this capacity, he currently represents Korys on the board of MyCartis. Prior to that, he was active as a Junior Analyst in the Paris offices of Fortis Bank (now BNP Paribas) at the Corporate Finance and Capital Markets department. He then joined iPierian, a San Francisco biotech start-up company, as a financial analyst.
Supervisory Board Member, member of the Governance & Remuneration Committee and member of the Audit Committee
Jan Willem Nieuwenhuize is an investment manager at ING Corporate Investments, the equity investments branch of ING Bank. Prior to joining ING in 2007, he worked for merchant bank Kempen & Co in the M&A and ECM team.
Supervisory Board Member, member of the Governance & Remuneration Committee
Peter Stein is the Chairman and Chief Executive Officer and principal shareholder of Norgine, an independent, specialty pharmaceutical company with operations throughout Europe. Prior to joining Norgine in 1987, Peter was a co-founder and Vice President of Invitron Corporation, a contract biomanufacturer formed as a spin-off from the Monsanto Company. He started his pharmaceutical career with Centocor.
Supervisory Board Member, member of the Audit Committee
Erik Leeuwaarden acquired a master degree in Law and Economics. He started his career with the Dutch Ministery of Finance for twelve years. Then he became CFO of Flowerauction FloraHolland from 1992 until 2014. He now advises and supervises companies in different fields as real estate, finance, IT and trade.
In 2015 Erik became a member of Agendia’s Supervisory Board.
Supervisory Board Member
Eric Esveld acquired a Master of Science Degree in Econometrics from Erasmus University in Rotterdam. Since 2001, Erik has been the CFO at Van Herk Groep, based in Rotterdam, The Netherlands.